Journals / The Anatolian Journal of Cardiology / 2020 / Cilt: 23 - Sayı: 6

Effects of surgical septal myectomy on survival in patients with hypertrophic obstructive cardiomyopathy

Pages
342–348
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Among the three groups, the myectomy group showed a lower rate of reaching the all-cause mortality withstatistically indistinguishable overall survival compared with patients with nonobstructive HCM (p=0.514).

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: The purpose of this study was to determine the effects of surgical resection of muscle layer on the long-term survival of patients withhypertrophic obstructive cardiomyopathy (HOCM).Methods: The original study cohort consisted of 552 patients with hypertrophic cardiomyopathy (HCM), including 380 patients with HOCM and172 patients with nonobstructive HCM.
📊
Key Findings & Data:All these patients had a definite diagnosis in our center from October 1, 2009, to December 31, 2012.
💡
Conclusion & Impact:Among the three groups, the myectomy group showed a lower rate of reaching the all-cause mortality withstatistically indistinguishable overall survival compared with patients with nonobstructive HCM (p=0.514).
🔬Design:Modeling & Simulation
📍Scope:2009 Verileri
⚙️Variables:Domain Parameters

Özet

Objective: The purpose of this study was to determine the effects of surgical resection of muscle layer on the long-term survival of patients withhypertrophic obstructive cardiomyopathy (HOCM).Methods: The original study cohort consisted of 552 patients with hypertrophic cardiomyopathy (HCM), including 380 patients with HOCM and172 patients with nonobstructive HCM. All these patients had a definite diagnosis in our center from October 1, 2009, to December 31, 2012. Theywere divided into three groups, viz., HOCM with myectomy group (n=194), nonoperated HOCM group (n=186), and nonobstructive HCM group(n=172). Median follow-up duration was 57.57±13.71 months, and the primary end point was a combination of mortality from all causes.Results: In this survival study, we compared the prognoses of patients with HOCM after myectomy, patients with nonoperated HOCM, andpatients with nonobstructive HCM. Among the three groups, the myectomy group showed a lower rate of reaching the all-cause mortality withstatistically indistinguishable overall survival compared with patients with nonobstructive HCM (p=0.514). Among patients with left ventricularoutflow tract (LVOT) obstruction, the overall survival in the myectomy group was noticeably better than that in the nonoperated HOCM group(log-rank p<0.001). Parameters that showed a significant univariate correlation with survival included age, previous atrial fibrillation (AF), NTproBNP, Cr, myectomy, and LV ejection fraction. When these variables were entered in the multivariate model, the only independent predictorsof survival were myotomy [hazard ratio (HR): 0.109; 95% CI: 0.013–0.877, p<0.037], age (HR: 1.047; 95% CI: 1.007–1.088, p=0.021), and previous AF(HR: 2.659; 95% CI: 1.022–6.919, p=0.021).Conclusion: Patients with HOCM undergoing myectomy appeared to suffer from a lower risk of reaching the all-cause mortality and demonstrated statistically indistinguishable overall survival compared with patients with nonobstructive HCM. Multivariate analysis clearly demonstratedmyectomy as a powerful, independent factor of survival, confirming that the differences in long-term survival recorded in this study may be dueto surgical improvement in the LVOT gradient. (Anatol J Cardiol 2020; 23: 342-8)

🔖

Cite This Article

MENG, X., LIANG, M., SHI, Y., ZHOU, S., ZHANG, W., GAO, C. (2020). Effects of surgical septal myectomy on survival in patients with hypertrophic obstructive cardiomyopathy. The Anatolian Journal of Cardiology, Cilt: 23 - Sayı: 6, 342–348. https://ajindex.com/articles/365684

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (11)

  1. Semsarian C, Ingles J, Maron MS, Maron BJ. New perspectives on the prevalence of hypertrophic cardiomyopathy. J Am Coll Cardiol 2015; 65: 1249-54
  2. Sen-Chowdhry S, Jacoby D, Moon JC, McKenna WJ. Update on hypertrophic cardiomyopathy and a guide to the guidelines. Nat Rev Cardiol 2016; 13: 651-75
  3. Maron BJ, Maron MS. Hypertrophic cardiomyopathy. Lancet 2013; 381: 242-55
  4. Nagueh SF, Groves BM, Schwartz L, Smith KM, Wang A, Bach RG, et al. Alcohol septal ablation for the treatment of hypertrophic obstructive cardiomyopathy. A multicenter North American registry. J Am Coll Cardiol 2011; 58: 2322-8
  5. Ball W, Ivanov J, Rakowski H, Wigle ED, Linghorne M, Ralph-Edwards A, et al. Long-term survival in patients with resting obstructive hypertrophic cardiomyopathy comparison of conservative versus invasive treatment. J Am Coll Cardiol 2011; 58: 2313-21
  6. Kirklin JW, Ellis FH Jr. Surgical relief of diffuse subvalvular aortic stenosis. Circulation 1961; 24: 739-42
  7. Morrow AG, Reitz BA, Epstein SE, Henry WL, Conkle DM, Itscoitz SB, et al. Operative treatment in hypertrophic subaortic stenosis. Techniques, and the results of pre and postoperative assessments in 83 patients. Circulation 1975; 52: 88-102
  8. Schönbeck MH, Brunner-La Rocca HP, Vogt PR, Lachat ML, Jenni R, Hess OM, et al. Long-term follow-up in hypertrophic obstructive cardiomyopathy after septal myectomy. Ann Thorac Surg 1998; 65: 1207-14
  9. Merrill WH, Friesinger GC, Graham TP Jr, Byrd BF 3rd, Drinkwater DC Jr, Christian KG, et al. Long-lasting improvement after septal myectomy for hypertrophic obstructive cardiomyopathy. Ann Thorac Surg 2000; 69: 1732-5
  10. Gersh BJ, Maron BJ, Bonow RO, Dearani JA, Fifer MA, Link MS, et al.; American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines; American Association for Thoracic Surgery; American Society of Echocardiography; American Society of Nuclear Cardiology; Heart Failure Society of America; Heart Rhythm Society; Society for Cardiovascular Angiography and Interventions; Society of Thoracic Surgeons. 2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2011; 124: e783-831
  11. Authors/Task Force members, Elliott PM, Anastasakis A, Borger MA, Borggrefe M, Cecchi F, et al. 2014 ESC Guidelines on diagnosis and management of hypertrophic c